DiaMedica Therapeutics (NASDAQ:DMAC) Shares Up 1.1%

DiaMedica Therapeutics Inc. (NASDAQ:DMAC)’s share price shot up 1.1% on Friday . The stock traded as high as $2.90 and last traded at $2.88. 9,783 shares traded hands during mid-day trading, a decline of 76% from the average session volume of 40,364 shares. The stock had previously closed at $2.85.

Analyst Ratings Changes

Several brokerages recently weighed in on DMAC. Oppenheimer reaffirmed an “outperform” rating and issued a $6.00 target price (down previously from $7.00) on shares of DiaMedica Therapeutics in a report on Thursday, March 21st. Craig Hallum assumed coverage on shares of DiaMedica Therapeutics in a report on Wednesday, April 24th. They set a “buy” rating and a $8.00 price objective for the company.

DiaMedica Therapeutics Stock Performance

The firm’s fifty day simple moving average is $2.80 and its 200 day simple moving average is $2.81. The firm has a market cap of $109.32 million, a P/E ratio of -5.14 and a beta of 1.75.

DiaMedica Therapeutics (NASDAQ:DMAC) last released its quarterly earnings data on Wednesday, March 20th. The company reported ($0.14) EPS for the quarter, meeting the consensus estimate of ($0.14). On average, equities research analysts predict that DiaMedica Therapeutics Inc. will post -0.67 earnings per share for the current year.

Institutional Trading of DiaMedica Therapeutics

Hedge funds have recently made changes to their positions in the business. Stonebridge Capital Advisors LLC purchased a new stake in shares of DiaMedica Therapeutics during the 3rd quarter valued at about $52,000. Vanguard Group Inc. raised its position in shares of DiaMedica Therapeutics by 26.3% during the 1st quarter. Vanguard Group Inc. now owns 1,013,522 shares of the company’s stock valued at $2,807,000 after buying an additional 211,351 shares in the last quarter. Paragon Associates & Paragon Associates II Joint Venture raised its position in shares of DiaMedica Therapeutics by 6.4% during the 4th quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 500,000 shares of the company’s stock valued at $1,420,000 after buying an additional 30,000 shares in the last quarter. Finally, Avantax Advisory Services Inc. purchased a new stake in shares of DiaMedica Therapeutics during the 4th quarter valued at about $36,000. 10.12% of the stock is currently owned by hedge funds and other institutional investors.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.